Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE IS EXPECTED TO REACH USD 25.30 BILLION BY 2027 FROM USD 11.30 BILLION IN 2021, GROWING AT A CAGR OF 14.37%.
The Biopharmaceutical Contract Manufacturing Market Size, Share, Growth Forecast By:
- Product: Finished Dosage Form (FDF) and Active Pharmaceutical Ingredients (APIs)
- Biologics: Monoclonal Antibodies (mAbs), Vaccines, and Others
- Expression System: Mammalian and Non-Mammalian
- Scale Of Operations: Commercial and Research (Clinical & Preclinical)
- Company Size: Large & Very Large Companies and Small & Mid-Sized Companies
- Geography: North America, Europe, APAC, Latin America, And Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Share & Forecast 2022–2027
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2027) | USD 25.30 Billion |
| Market Size (2021) | USD 11.30 Billion |
| CAGR (2022-2027) | 14.37% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Product, Biologics, Expression System, Scale Of Operations, Company Size, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
MARKET INSIGHTS
The global biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 14.37% from 2022 to 2027. It is projected to cross $25.20 Billion by 2027 from $11 billion in 2021. The market is influenced by parameters such as uptake of branded biologics and biosimilars, mandatory immunization programs for newborns and children to prevent a wide range of diseases, and ongoing global COVID-19 vaccine programs to curb the spread of the pandemic are contributing to the global market growth.
The biopharmaceutical contract manufacturing market comprises advanced technology, new scientific advances, and highly complex research and development (R&D) companies. A contract manufacturing organization (CMO), also known as a contract development and manufacturing organization (CDMO), is a company that provides the pharmaceutical industry with contract-based drug development and drug manufacturing services. With time, the CMO provides pharmaceutical and biopharmaceutical manufacturers with one of the essential assets in today's fast-paced world. By outsourcing the manufacturing process, pharmaceutical and biopharmaceutical manufacturers can prioritize internal capabilities and free up the internal resources needed to improve process efficiency, further boosting the growth of the biopharmaceutical contract manufacturing market.
MARKET TRENDS AND DRIVERS
Robust Biopharmaceuticals Pipeline
Cell & Gene therapies are emerging as one of the most dynamic fields in medicine with an increased number of ongoing research and development activities. Many vendors and research organizations are engaged in the R&D of cell & gene therapies. The key vendors increasingly conduct clinical trials to gain regulatory approval in the U.S., which has largely untapped potential.
In the cell & gene therapy market, a rising number of product approvals, rapidly increasing investment in regenerative medicines and biologics, and increasing demand for cell and gene therapies due to the constant demand for severe disease care drive the global biopharmaceutical contract manufacturing market growth.
The pipeline for biosimilars continues to grow with the FDA approval of 30 biosimilars and 21 biosimilars launched in the U.S. by July 2021. The total number of biosimilars in the pipeline database grew by 208% in 2020. The number of marketed biosimilars also increased by 226% in the past seven years. The present number of biosimilars in the preclinical phase in 2020 vs. 2013 has increased similarly by 200%. The growth has further helped expand the biopharmaceutical contract manufacturing market. By 2018, the European Union had approved more than 40 biosimilars.
Increased Manufacturing of Gene Therapies by CMOs
In the past several years, gene therapies have continued their rising trend in the biopharmaceutical industry. Biopharma companies are investing in these therapies, and the FDA has encouraged gene therapy development. As gene therapies cost time and money to develop and manufacture, many biopharmaceutical companies are turning to CMOs (Contract Manufacturing Organizations). For biopharmaceutical companies with no practical manufacturing experience, adopting an established CMO can reduce these operational risks and reduce the manufacturing time. This can be achieved by leveraging the CMO's expertise and skills in installing facilities and navigating regulatory systems. This has helped the biopharmaceutical contract manufacturing market to grow in the gene therapy market with the help of CMOs.
Increase Biologics Manufacturing Outsourcing by Pharma and Biotech Companies
The most pressing problems the industry has faced for quite some time are massive R&D spending and the declining return on investment, regulatory and government pressures on drug prices, and the need to improve productivity and efficiency throughout the value chain. To counter this problem biopharmaceutical manufacturing market comes to help. Outsourcing is a common way for pharmaceutical companies to increase operational efficiency, expand their geographic footprint, and expand their therapeutic expertise and on-demand services.
Larger and more established companies continue to look for partners to outsource established products to free up internal capacity for new and upcoming developments in the pipeline. This trend is not so surprising. Outsourcing helps enterprises save on resources, infrastructure, and other overhead and contribute to the biopharmaceutical contract manufacturing market. SMEs are still a significant source of innovation, with an active pipeline of products under development. Many SMEs do not have the manufacturing capacity and often do not plan to develop these core competencies, so they want to move their products to the clinical stage and ultimately to commercial manufacturing operations, which is extensively provided by the biopharmaceutical contract manufacturing market.
Overall, pharmaceutical and biotechnology companies' decision to outsource manufacturing directly impacts the contract manufacturing market for bio pharmacy. In this analysis, CMO customers are categorized into
a) companies that do not do in-house biomanufacturing (virtual companies)
b) companies with in-house biomanufacturing.
For virtual businesses, outsourcing all production is usually part of the overall corporate strategy, which boosts the market, as most virtual enterprises lack the resources and products to justify ownership of a manufacturing facility. On the other hand, companies with organic production bases or resources to build internal capabilities are adopting different production strategies depending on the specific situation and strategy.
A Surge in Manufacturing Capacity Expansion Post Covid by CDMOs and CMOs
Over the next three years, the total manufacturing capacity will increase by 60% as the CMO invests to meet future demand. Such factors make a positive impact on the biopharmaceutical contract manufacturing market. Most of this new capacity supports the production of mammalian cell cultures. Given these expansion plans, capacity utilization rates remain in the low 70% range throughout the forecast period. In addition to expanding production capacity, CMOs invest in other services to meet future customers' needs. CMO plans to invest heavily in manufacturing, analytical, new research centers, and productivity and quality improvements in cell and gene therapy.
In December 2021, Fujifilm Diosynth announced plans to invest USD 533 million to include a viral gene therapy facility and a mammalian cell culture facility in Billingham, Teesside, UK. The new facility is scheduled to be ready by the end of 2023. This investment is part of the USD 977 million global investment package that the company first outlined in June 2021.
Product Launches & Regulatory Approvals
Vendors strategically focus on developing and marketing single-use bioprocessing products to remain competitive and gain a foothold in the market. Product approvals and launches, coupled with R&D activities, help vendors to expand their footprint, drive market growth, and maintain their position in the gene therapy market. Vendors are also aggressively bringing innovative, advanced therapies to penetrate and harness the tremendous growth potential of the market.
Some vendors invest heavily in R&D activities and plan to launch innovative products in the coming years. For instance, companies such as Boehringer Ingelheim GmbH, AbbVie Inc., Lonza, AGC Biologics, Catalent, Samsung Biologics, and WuXi Biologics have a significant market share owing to their continuous involvement in product innovations and launches are making significant contributions to the growth of the biopharmaceutical contract manufacturing market. Product approvals and launches between 2015 and early 2021 positively impacted the market.
MARKET SEGMENTATION
- The global biopharmaceutical contract manufacturing market by product type segments into Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms. The Finished Dosage Form (FDF) segment reported a major share of around 50.52% in 2021. The FDF segment is estimated to be higher because it is an important stage in the product life cycle and can only be achieved if the manufacturing facilities of the pharmaceutical company or outsourced manufacturing organization are of a high standard.
- The demand for the biologics segment in the global biopharmaceutical contract manufacturing market has tremendously increased. Among the biologics sector, the monoclonal antibodies (mAbs) sector reported a significant share in the market. The mAbs segment is estimated to be higher due to the looming entry of several companies, including big pharma, small biotech, and generic participants, into the global biosimilars development will boost the market exponentially.
- The mammalian segment holds a higher global biopharmaceutical contract manufacturing market share under the impression system category because the central pillar of the biotechnology and pharmaceutical industry continues to be the development of biopharmaceuticals made from transgenic mammalian cell lines. In addition, mammalian-expressed biopharmaceuticals make up the most significant proportion of candidates for the biopharmaceutical pipeline.
- Among scale of operation, the commercial segment reported a major share in the market. The commercial segment is estimated to be higher due to the growing infectious diseases and the onset of epidemics and pandemics; there is a huge demand for manufacturing billion doses of biotechnology products within months. It is a highly challenging task with limitations in small-scale manufacturing for clinical trials, clinical testing timelines involving multiple phases, and large-scale drug substance and drug product manufacturing. Due to this, it holds the largest biopharmaceutical contract manufacturing market share in the commercial segment.
- Based on company size, large sized companies segment reported a significant share of around 58.66% in the biopharmaceutical contract manufacturing market. The large company’s segment is estimated to be higher because large biopharmaceutical companies rely on CMOs for large-scale biologics production. The large biopharmaceutical companies focus on drug development over manufacturing; CMOs can provide access to capacity without investing in facilities.
GEOGRAPHICAL ANALYSIS
- The global biopharmaceutical contract manufacturing market is categorized into regions of North America, Europe, APAC, Latin America, and the Middle East & Africa. North America dominated the global market and accounted for a revenue share of 37.21%, followed by Europe.
- The APAC marks the fastest-growing region for market growth. Emerging countries such as China and Japan are the major players due to low labor costs and increased outsourcing of biologics manufacturing.
- North America dominates the biopharmaceutical contract manufacturing market as the country is well established, with prominent biopharmaceutical manufacturing companies based in the region. The rise in drug development has dramatically increased the biopharmaceutical contract manufacturing demand in this region. The U.S. is the major revenue contributor in North America mainly due to increased demand for cell and gene therapy and the prominent presence of companies in the U.S.
- The increasing elderly population, the prevalence of autoimmune diseases, respiratory disorders, cancer, etc., are increasing demand for biopharmaceuticals, and expanding biopharma and biotech industry are significant factors contributing to the growth of the biopharmaceutical contract manufacturing market in Europe. More significant investments due to the high focus of government bodies on R&D across European regions are driving the biopharmaceutical outsourcing market.
- Increasing expenditure on regenerative medicine development and clinical trials gives new hope for growth in cell and gene therapy drugs. Also, increasing clinical trials of stem cell therapies and gene therapies drive the growth of manufacturing companies, which will trigger the development of the biopharmaceutical contract manufacturing market in Latin America.
COMPETITIVE LANDSCAPE
- The biopharmaceutical contract manufacturing market is highly competitive, with a large pool of global, regional, and local companies involved in the contract manufacturing of various biopharmaceuticals. Vendors in this market compete based on a wide range of services offered, pricing, quality, and scale-up production of biopharmaceuticals.
- The market is concentrated with key comapnies such as Samsung biologics, Lonza and Boehringer Ingelheim GmbH.
- Other emerging biopharmaceutical contract manufacturing companies include AbbVie, Inc., Catalent, Emergent BioSolutions, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Pfizer CentreOne, Serum Institute of India, and WuXi biologics. These companies hold a significant share in the global market and focus on continuous expansion in biopharmaceutical contract manufacturing, further intensifying the competition in the worldwide market.
- Samsung Biologics is one of the active biopharmaceutical contract manufacturing companies that invested a considerable amount in enhancing their manufacturing capacity by volume. The company is investing around USD 2 billion in its super plant in Incheon, South Korea, with a 256,000 liters capacity.
- Vendors in the biopharmaceutical contract manufacturing market are actively involved in strategic acquisitions and agreements to develop their proprietary technologies and increase their brand image in the industry. Catalent made one such acquisition and expanded its early development capabilities through the acquisition of Pharmatek Laboratories.
Frequently Asked Questions
What is the global biopharmaceutical contract manufacturing market size?
What is the expected growth rate of the global biopharmaceutical contract manufacturing market?
Who are the key companies in the biopharmaceutical contract manufacturing market?
Which trends are driving the growth of the global biopharmaceutical contract manufacturing market?
Which region holds the highest global biopharmaceutical contract manufacturing market share?
The global biopharmaceutical contract manufacturing market is expected to grow at a CAGR of approximately 14.37% from 2022 to 2027.
The following factors are likely to contribute to the growth of the global biopharmaceutical contract manufacturing market during the forecast period:
- Biologics Manufacturing Outsourcing By Pharma and Biotech Companies
- Rapid Expansion Of Biopharmaceuticals Manufacturing Service Offerings By CMOs & CDMOs
- Surge In Manufacturing Capacity Expansion Post Covid By CDMOs and CMOs
- High Demand for Biological Products
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the global biopharmaceutical contract manufacturing market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
- Boehringer Ingelheim
- Business Overview
- Service Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- Lonza
- Samsung Biologics
Key Companies
- AbbVie
- Business Overview
- Service Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- Catalent
- Emergent BioSolutions
- FUJIFILM
- Merck KGaA
- Pfizer
- Serum Institute of India
- WuXi Biologics
Other Prominent Vendors
- AGC Biologics
- Business Overview
- Service Offerings
- Ajinomoto
- Albany Molecular Research (AMRI)
- Asymchem
- Biocon
- Cobra Biologics
- Charles River Laboratories
- Goodwin Biotechnology
- KBI Biopharma
- Sanofi
- Bavarian Nordic
- Wacker Biotech B.V
- Jubilant HollisterStier
- National Resilience
- Novasep
- Kemwell Biopharma
- Midas Pharma
- Alcami
- Cambrex
- Pharmaceutics International
- Singota Solutions
- Thermo Fisher Scientific
- Binexc
- Canton Biologics
- ChemPartner
- Cytovance Biologics
Segmentation by Product Type
- Finished Dosage Form (FDF)
- Active Pharmaceutical Ingredients (APIs)
Segmentation by Biologics
- Monoclonal Antibodies (mAbs)
- Vaccines
- Others
Segmentation by Expression System
- Mammalian
- Non-Mammalian
Segmentation by Scale Of Operations
- Commercial
- Research (Clinical & Preclinical)
Segmentation by Company Size
- Large & Very Large Companies
- Small & Mid-Sized Companies
Segmentation by Geography
- Europe
- Germany
- UK
- France
- Switzerland
- Italy
- Spain
- APAC
- China
- Japan
- South Korea
- Australia
- India
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 2021-2027 (& BILLION)
EXHIBIT 4 PIPELINE OF BIOSIMILARS BY PHASES OF DEVELOPMENT (2013 AND 2020)
EXHIBIT 5 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATIONS
EXHIBIT 6 IMPACT OF M&AS AMONG BIOPHARMACEUTICAL MANUFACTURERS
EXHIBIT 7 IMPACT OF ROBUST BIOPHARMACEUTICALS PIPELINE
EXHIBIT 8 PIPELINE OF BIOSIMILARS BY PHASES OF DEVELOPMENT (2013 AND 2020)
EXHIBIT 9 INDUSTRIAL SPONSORED TRIALS OF C> IN THE PIPELINE
EXHIBIT 10 VACCINES IN PIPELINE FOR VARIOUS INFECTIOUS DISEASES
EXHIBIT 11 IMPACT OF INCREASED MANUFACTURING OF GENE THERAPIES BY CMOS
EXHIBIT 12 MAJOR ADVANTAGES OF ENGAGING WITH CMOS
EXHIBIT 13 FACTORS CONSIDERED IN PARTNERSHIP WITH CONTRACT MANUFACTURERS
EXHIBIT 14 IMPACT OF PRODUCT LAUNCHES & REGULATORY APPROVALS
EXHIBIT 15 IMPACT OF INCREASE BIOLOGICS MANUFACTURING OUTSOURCING BY PHARMA AND BIOTECH COMPANIES
EXHIBIT 16 CATEGORIES OF BIOMANUFACTURERS OUTSOURCING ACTIVITIES 2017 (% SHARE)
EXHIBIT 17 IMPACT OF RAPID EXPANSION OF BIOPHARMACEUTICALS MANUFACTURING SERVICE OFFERINGS
EXHIBIT 18 IMPACT OF SURGE IN MANUFACTURING CAPACITY EXPANSION POST COVID BY CDMOS AND CMOS
EXHIBIT 19 IMPACT OF HIGH DEMAND FOR BIOLOGICAL PRODUCTS
EXHIBIT 20 NEW DRUG THERAPIES APPROVED BY US-FDA
EXHIBIT 21 IMPACT OF HIGH COST OF TREATMENT TO RESTRAIN BIOLOGICS CONTRACT MANUFACTURING MARKET
EXHIBIT 22 IMPACT OF LACK OF STORAGE INFRASTRUCTURE & LIMITATIONS ASSOCIATED WITH SUPPLY CHAIN
EXHIBIT 23 MAJOR BARRIERS TO EFFECTIVE VACCINE HANDLING AND STORAGE (% SHARE)
EXHIBIT 24 IMPACT OF HIGH COST OF ESTABLISHING BIOLOGICS MANUFACTURING FACILITY
EXHIBIT 25 TOP 10 GLOBAL MANUFACTURING HUBS
EXHIBIT 26 MAJOR GROWTH FACTORS OF BIOPHARMACEUTICAL MARKET
EXHIBIT 27 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 2021–2027 ($ BILLION)
EXHIBIT 28 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY
EXHIBIT 29 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT
EXHIBIT 30 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS
EXHIBIT 31 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM
EXHIBIT 32 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION
EXHIBIT 33 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE
EXHIBIT 34 FIVE FORCES ANALYSIS 2021
EXHIBIT 35 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 36 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY CONTRACT TYPE
EXHIBIT 37 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT: INCREMENTAL GROWTH
EXHIBIT 38 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT: ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY FINISHED DOSAGE FORM: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY FDF 2021–2027 ($ BILLION)
EXHIBIT 41 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY ACTIVE PHARMACEUTICAL INGREDIENTS (APIS): INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY APIS 2021–2027 ($ BILLION)
EXHIBIT 43 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 44 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS
EXHIBIT 45 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS: INCREMENTAL GROWTH
EXHIBIT 46 DIFFERENT TYPES OF COVID-19 VACCINES UNDER RESEARCH BY 2020
EXHIBIT 47 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS: ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MONOCLONAL ANTIBODIES (MABS): INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MONOCLONAL ANTIBODIES (MABS) 2021–2027 ($ BILLION)
EXHIBIT 50 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY VACCINES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY VACCINE 2021–2027 ($ BILLION)
EXHIBIT 52 CELL AND GENE THERAPY PRODUCT APPROVALS & LAUNCH DETAILS
EXHIBIT 53 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY VACCINE: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 54 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY OTHERS 2021–2027 ($ BILLION)
EXHIBIT 55 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 56 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM
EXHIBIT 57 DIFFERENT EXPRESSION SYSTEMS OFFERED BY CDMOS
EXHIBIT 58 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM: INCREMENTAL GROWTH
EXHIBIT 59 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM: ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MAMMALIAN: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MAMMALIAN 2021–2027 ($ BILLION)
EXHIBIT 62 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY NON-MAMMALIAN: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY NON-MAMMALIAN 2021–2027 ($ BILLION)
EXHIBIT 64 INCREMENTAL GROWTH BY SCALE OF OPERATIONS 2021 & 2027
EXHIBIT 65 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATIONS
EXHIBIT 66 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION: INCREMENTAL GROWTH
EXHIBIT 67 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION: ABSOLUTE GROWTH
EXHIBIT 68 FDA-APPROVED COMMERCIALIZED GENE THERAPY PRODUCTS IN US
EXHIBIT 69 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMMERCIAL SEGMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 TOP SELLING BIOPHARMACEUTICALS DRUGS WORLDWIDE IN 2019 ($ BILLION)
EXHIBIT 71 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMMERCIAL 2021–2027 ($ BILLION)
EXHIBIT 72 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY RESEARCH (CLINICAL & PRECLINICAL) SEGMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY RESEARCH (CLINICAL & PRECLINICAL) 2021–2027 ($ BILLION)
EXHIBIT 74 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 75 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE
EXHIBIT 76 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE: INCREMENTAL GROWTH
EXHIBIT 77 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE: INCREMENTAL GROWTH
EXHIBIT 78 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY LARGE COMPANIES SEGMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY LARGE COMPANIES 2021–2027 ($ BILLION)
EXHIBIT 80 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY LARGE COMPANIES SEGMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SMALL & MID-SIZED COMPANIES 2021–2027 ($ BILLION)
EXHIBIT 82 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 83 GLOBAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY
EXHIBIT 84 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY COUNTRIES
EXHIBIT 85 COMPARISON OF PHARMA & BIOTECH COMPANIES WILLING TO OUTSOURCE BIOPHARMACEUTICAL MANUFACTURING IN SELECT COUNTRIES 2020 & 2026
EXHIBIT 86 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 87 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 88 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA: KEY COUNTRIES
EXHIBIT 89 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 90 NUMBER OF REGENERATIVE MEDICINE MANUFACTURERS IN NORTH AMERICA 2017-2021
EXHIBIT 91 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA 2021–2027 ($ BILLION)
EXHIBIT 92 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 93 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 94 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 95 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 96 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 97 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 98 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN US 2021–2027 ($ BILLION)
EXHIBIT 99 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN CANADA 2021–2027 ($ BILLION)
EXHIBIT 100 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE: KEY COUNTRIES
EXHIBIT 101 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 102 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE 2021–2027 ($ BILLION)
EXHIBIT 103 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 104 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 105 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 106 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 107 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 108 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 109 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN GERMANY 2021–2027 ($ BILLION)
EXHIBIT 110 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN FRANCE 2021–2027 ($ BILLION)
EXHIBIT 111 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN UK 2021–2027 ($ BILLION)
EXHIBIT 112 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN SWITZERLAND 2021–2027 ($ BILLION)
EXHIBIT 113 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN ITALY 2021–2027 ($ BILLION)
EXHIBIT 114 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN SPAIN 2021–2027 ($ BILLION)
EXHIBIT 115 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC: KEY COUNTRIES
EXHIBIT 116 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 117 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN APAC 2021–2027 ($ BILLION)
EXHIBIT 118 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 119 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 120 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 121 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 122 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 123 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 124 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN CHINA 2021–2027 ($ BILLION)
EXHIBIT 125 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN JAPAN 2021–2027 ($ BILLION)
EXHIBIT 126 CELL & GENE THERAPY CLINICAL TRIALS IN SOUTH KOREA 2021
EXHIBIT 127 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN SOUTH KOREA 2021–2027 ($ BILLION)
EXHIBIT 128 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN INDIA 2021–2027 ($ BILLION)
EXHIBIT 129 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN AUSTRALIA 2021–2027 ($ BILLION)
EXHIBIT 130 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA: KEY COUNTRIES
EXHIBIT 131 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 132 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN LATIN AMERICA 2021–2027 ($ BILLION)
EXHIBIT 133 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 134 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 135 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 136 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 137 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 138 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 139 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN BRAZIL 2021–2027 ($ BILLION)
EXHIBIT 140 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MEXICO 2021–2027 ($ BILLION)
EXHIBIT 141 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN ARGENTINA 2021–2027 ($ BILLION)
EXHIBIT 142 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA: KEY COUNTRIES
EXHIBIT 143 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 144 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN MIDDLE EAST & AFRICA 2021–2027 ($ BILLION)
EXHIBIT 145 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 146 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 147 INCREMENTAL GROWTH BY EXPRESSION SYSTEM 2021 & 2027
EXHIBIT 148 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 149 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 150 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 151 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN TURKEY 2021–2027 ($ BILLION)
EXHIBIT 152 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN SAUDI ARABIA 2021–2027 ($ BILLION)
EXHIBIT 153 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN UAE 2021–2027 ($ BILLION)
EXHIBIT 154 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN SOUTH AFRICA 2021–2027 ($ BILLION)
EXHIBIT 155 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY VENDORS STRENGTHS & CAPABILITIES ASSESSMENT
EXHIBIT 156 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VENDOR RANKING 2022 (BY MANUFACTURING CAPACITY VOLUME)
EXHIBIT 157 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 158 BOEHRINGER INGELHEIM: TOTAL SALES 2019-2021 ($ BILLION)
EXHIBIT 159 BOEHRINGER INGELHEIM: REVENUE BY BUSINESS UNIT (%)
EXHIBIT 160 BOEHRINGER INGELHEIM: REVENUE BY REGION (%)
EXHIBIT 161 LONZA: TOTAL SALES 2019-2021 ($ MILLION)
EXHIBIT 162 LONZA: REVENUE BY REPORTABLE DIVISIONS (%)
EXHIBIT 163 LONZA: REVENUE BY REGION (%)
EXHIBIT 164 SAMSUNG BIOLOGICS: TOTAL SALES 2019-2021 ($ MILLION)
EXHIBIT 165 SAMSUNG BIOLOGICS: REVENUE SHARE BY PRODUCT TYPE 2021 (%)
EXHIBIT 166 SAMSUNG BIOLOGICS: REVENUE SHARE BY GEOGRAPHY 2021 (%)
EXHIBIT 167 ABBVIE: TOTAL SALES 2019-2021 ($ BILLION)
EXHIBIT 168 ABBVIE: REVENUE BY RESEARCH & DEVELOPMENT EXPENDITURE ($ BILLION)
EXHIBIT 169 ABBVIE: REVENUE BY REGION ($ BILLION)
EXHIBIT 170 CATALENT: TOTAL SALES 2019-2021 ($ MILLION)
EXHIBIT 171 CATALENT: REVENUE BY BUSINESS SEGMENT 2021 (%)
EXHIBIT 172 FUJIFILM: TOTAL SALES 2018-2020 ($ BILLION)
EXHIBIT 173 FUJIFILM: REVENUE BY BUSINESS SEGMENT (%)
EXHIBIT 174 MERCK KGAA: TOTAL SALES 2019-2021 ($ BILLION)
EXHIBIT 175 MERCK KGAA: REVENUE SHARE BY BUSINESS SEGMENT (%)
EXHIBIT 176 MERCK KGAA: REVENUE SHARE BY REGION (%)
EXHIBIT 177 PFIZER: TOTAL SALES 2019-2021 ($ BILLION)
EXHIBIT 178 PFIZER: RESEARCH & DEVELOPMENT EXPENDITURE ($ BILLION)
EXHIBIT 179 PFIZER: REVENUE SHARE BY OPERATING SEGMENT ($ BILLION)
EXHIBIT 180 WUXI BIOLOGICS: TOTAL SALES 2019-2021 ($ BILLION)
EXHIBIT 181 WUXI BIOLOGICS: REVENUE BY REGION ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 MAJOR INVESTMENTS BY CMOS IN GENE THERAPY DEVELOPMENT
TABLE 4 LIST OF RECENT MERGER & ACQUISITIONS AMONG BIOPHARMACEUTICAL CONTRACT MANUFACTURERS
TABLE 5 BIOPHARMACEUTICAL PIPELINE DRUGS
TABLE 6 MAJOR INVESTMENTS BY CMOS IN GENE THERAPY DEVELOPMENT
TABLE 7 BIOPHARMACEUTICAL PIPELINE DRUGS
TABLE 8 DNA TO FILL-FINISH SERVICE OFFERING MAJOR CDMOS
TABLE 9 COST OF KYMRIAH IN DIFFERENT REGIONS
TABLE 10 VACCINE CANDIDATES IN DEVELOPMENT
TABLE 11 COMMERCIAL VACCINE CANDIDATES IN THE WORLD
TABLE 12 BIOPHARMACEUTICALS IN CLINICAL TRIALS BY PRODUCT CATEGORIES
TABLE 13 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 14 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY PRODUCT 2021−2027 (%)
TABLE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 16 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY BIOLOGICS 2021−2027 (%)
TABLE 17 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 18 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 19 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 20 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY SCALE OF OPERATION 2021−2027 (%)
TABLE 21 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 22 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN NORTH AMERICA BY COMPANY SIZE 2021−2027 (%)
TABLE 23 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY PRODUCT 2021−2027 ($ BILLION)
TABLE 24 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY PRODUCT 2021−2027 (%)
TABLE 25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY BIOLOGICS 2021−2027 (%)
TABLE 27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 29 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 30 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY SCALE OF OPERATION 2021−2027 (%)
TABLE 31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 32 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN EUROPE BY COMPANY SIZE 2021−2027 (%)
TABLE 33 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY PRODUCT 2021−2027 ($ BILLION)
TABLE 34 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY PRODUCT 2021−2027 (%)
TABLE 35 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 36 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY BIOLOGICS 2021−2027 (%)
TABLE 37 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 38 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 39 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 40 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY SCALE OF OPERATION 2021−2027 (%)
TABLE 41 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 42 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN APAC BY COMPANY SIZE 2021−2027 (%)
TABLE 43 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 44 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY PRODUCT 2021−2027 (%)
TABLE 45 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 46 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY BIOLOGICS 2021−2027 (%)
TABLE 47 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 48 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 49 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 50 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY SCALE OF OPERATION 2021−2027 (%)
TABLE 51 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 52 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN LATIN AMERICA BY COMPANY SIZE 2021−2027 (%)
TABLE 53 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 54 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY PRODUCT 2021−2027 (%)
TABLE 55 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 56 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY BIOLOGICS 2021−2027 (%)
TABLE 57 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 58 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 59 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 60 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY SCALE OF OPERATION 2021−2027 (%)
TABLE 61 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 62 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET IN MIDDLE EAST & AFRICA BY COMPANY SIZE 2021−2027 (%)
TABLE 63 BOEHRINGER INGELHEIM: MAJOR SERVICE OFFERINGS
TABLE 64 LONZA: MAJOR SERVICE OFFERINGS
TABLE 65 SAMSUNG BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 66 ABBVIE: MAJOR SERVICE OFFERINGS
TABLE 67 CATALENT: MAJOR SERVICE OFFERINGS
TABLE 68 EMERGENT BIOSOLUTIONS: MAJOR SERVICE OFFERINGS
TABLE 69 FUJIFILM: MAJOR SERVICE OFFERINGS
TABLE 70 MERCK KGAA: MAJOR SERVICE OFFERINGS
TABLE 71 PFIZER: MAJOR SERVICE OFFERINGS
TABLE 72 SERUM INSTITUTE OF INDIA: MAJOR SERVICE OFFERINGS
TABLE 73 WUXI BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 74 AGC BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 75 AJINOMOTO: MAJOR SERVICE OFFERINGS
TABLE 76 ALBANY MOLECULAR RESEARCH: MAJOR SERVICE OFFERINGS
TABLE 77 ASYMCHEM: MAJOR SERVICE OFFERINGS
TABLE 78 BIOCINA: MAJOR SERVICE OFFERINGS
TABLE 79 BIOCON: MAJOR SERVICE OFFERINGS
TABLE 80 COBRA BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 81 CHARLES RIVER LABORATORIES: MAJOR SERVICE OFFERINGS
TABLE 82 GOODWIN BIOTECHNOLOGY: MAJOR SERVICE OFFERINGS
TABLE 83 KBI BIOPHARMA: MAJOR SERVICE OFFERINGS
TABLE 84 SANOFI: MAJOR SERVICE OFFERINGS
TABLE 85 BAVARIAN NORDIC: MAJOR SERVICE OFFERINGS
TABLE 86 WACKER BIOTECH B.V: MAJOR SERVICE OFFERINGS
TABLE 87 JUBILANT HOLLISTERSTIER: MAJOR SERVICE OFFERINGS
TABLE 88 NATIONAL RESILIENCE: MAJOR SERVICE OFFERINGS
TABLE 89 NOVASEP: MAJOR SERVICE OFFERINGS
TABLE 90 KEMWELL BIOPHARMA: MAJOR SERVICE OFFERINGS
TABLE 91 MIDAS PHARMA: MAJOR SERVICE OFFERINGS
TABLE 92 ALCAMI: MAJOR SERVICE OFFERINGS
TABLE 93 CAMBREX: MAJOR SERVICE OFFERINGS
TABLE 94 PHARMACEUTICS INTERNATIONAL: MAJOR SERVICE OFFERINGS
TABLE 95 SINGOTA SOLUTIONS: MAJOR SERVICE OFFERINGS
TABLE 96 THERMO FISHER SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 97 BINEX: MAJOR SERVICE OFFERINGS
TABLE 98 CANTON BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 99 CHEMPARTNER: MAJOR SERVICE OFFERINGS
TABLE 100 CYTOVANCE BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 101 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 102 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 103 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 104 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 105 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 106 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 107 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 108 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 109 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 110 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 111 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 112 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY PRODUCT 2021−2027 (%)
TABLE 113 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 114 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 115 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 116 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 117 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 118 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 119 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 120 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 121 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 122 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 123 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 ($ BILLION)
TABLE 124 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 125 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 126 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM2021−2027 (%)
TABLE 127 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 128 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 129 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 130 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 131 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 132 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 133 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 134 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 135 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 ($ BILLION)
TABLE 136 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY EXPRESSION SYSTEM 2021−2027 (%)
TABLE 137 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 138 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 139 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 140 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 141 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 142 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 143 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 144 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 145 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 146 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 147 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 ($ BILLION)
TABLE 148 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 149 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 150 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 151 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 152 NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 153 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 154 EUROPE BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 155 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 156 APAC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 157 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 158 LATIN AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 159 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 160 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 161 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 162 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 163 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) 2021−2027 ($ BILLION)
TABLE 164 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) 2021−2027 (%)
TABLE 165 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY FINISHED DOSAGE FORM (FDF) 2021−2027 ($ BILLION)
TABLE 166 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY FINISHED DOSAGE FORM (FDF) 2021−2027 (%)
TABLE 167 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MONOCLONAL ANTIBODIES (MABS) 2021−2027 ($ BILLION)
TABLE 168 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MONOCLONAL ANTIBODIES (MABS) 2021−2027 (%)
TABLE 169 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY VACCINES 2021−2027 ($ BILLION)
TABLE 170 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY VACCINES 2021−2027 (%)
TABLE 171 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY OTHERS 2021−2027 ($ BILLION)
TABLE 172 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY OTHERS 2021−2027 (%)
TABLE 173 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MAMMALIAN 2021−2027 ($ BILLION)
TABLE 174 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY MAMMALIAN 2021−2027 (%)
TABLE 175 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY NON-MAMMALIAN 2021−2027 ($ BILLION)
TABLE 176 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY NON-MAMMALIAN 2021−2027 (%)
TABLE 177 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMMERCIAL 2021−2027 ($ BILLION)
TABLE 178 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY COMMERCIAL 2021−2027 (%)
TABLE 179 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY RESEARCH (CLINICAL & PRECLINICAL) 2021−2027 ($ BILLION)
TABLE 180 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY RESEARCH (CLINICAL & PRECLINICAL) 2021−2027 (%)
TABLE 181 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY LARGE COMPANIES 2021−2027 ($ BILLION)
TABLE 182 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY LARGE COMPANIES 2021−2027 (%)
TABLE 183 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SMALL & MID-SIZED COMPANIES 2021−2027 ($ BILLION)
TABLE 184 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SMALL & MID-SIZED COMPANIES 2021−2027 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 NEED FOR CMO
7.1.2 BENEFITS RELATED TO CMOS
8 PREMIUM INSIGHTS
8.1 OVERVIEW
8.1.1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SCENARIO
8.1.2 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATIONS
9 MARKET OPPORTUNITIES & TRENDS
9.1 M&AS AMONG BIOPHARMACEUTICAL MANUFACTURERS
9.2 ROBUST BIOPHARMACEUTICALS PIPELINE
9.3 INCREASED MANUFACTURING OF GENE THERAPIES BY CMOS
9.4 PRODUCT LAUNCHES & REGULATORY APPROVALS
10 MARKET GROWTH ENABLERS
10.1 INCREASE BIOLOGICS MANUFACTURING OUTSOURCING BY PHARMA AND BIOTECH COMPANIES
10.2 EXPANSION OF BIOPHARMACEUTICAL MANUFACTURING SERVICE OFFERINGS
10.3 SURGE IN MANUFACTURING CAPACITY EXPANSION POST-COVID BY CDMOS AND CMOS
10.4 HIGH DEMAND FOR BIOLOGICAL PRODUCTS
11 MARKET RESTRAINTS
11.1 HIGH COST OF TREATMENT TO RESTRAIN BIOLOGICS CONTRACT MANUFACTURING MARKET
11.2 LACK OF STORAGE INFRASTRUCTURE & LIMITATIONS ASSOCIATED WITH SUPPLY CHAIN
11.3 HIGH COST OF ESTABLISHING BIOLOGICS MANUFACTURING FACILITY
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.2.1 INSIGHTS BY GEOGRAPHY
12.2.2 INSIGHTS BY PRODUCT
12.2.3 INSIGHTS BY BIOLOGICS
12.2.4 INSIGHTS BY EXPRESSION SYSTEM
12.2.5 INSIGHTS BY SCALE OF OPERATION
12.2.6 INSIGHTS BY COMPANY SIZE
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 FINISHED DOSAGE FORM
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
14 BIOLOGICS
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 MONOCLONAL ANTIBODIES (MABS)
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 VACCINES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
15 EXPRESSION SYSTEM
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 MAMMALIAN
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 NON-MAMMALIAN
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
16 SCALE OF OPERATIONS
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 COMMERCIAL
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.4 RESEARCH (CLINICAL & PRECLINICAL)
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
17 COMPANY SIZE
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 LARGE COMPANIES
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.4 SMALL & MID-SIZED COMPANIES
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
18 GEOGRAPHY
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 GEOGRAPHIC OVERVIEW
18.2.1 BIOPHARMACEUTICALS OUTSOURCING AT A GLANCE
19 NORTH AMERICA
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 NORTH AMERICA: PRODUCT SEGMENTATION
19.2.2 NORTH AMERICA: BIOLOGICS SEGMENTATION
19.2.3 NORTH AMERICA: EXPRESSION SYSTEM SEGMENTATION
19.2.4 NORTH AMERICA: SCALE OF OPERATION SEGMENTATION
19.2.5 NORTH AMERICA: COMPANY SIZE SEGMENTATION
19.3 KEY COUNTRIES
19.3.1 US: MARKET SIZE & FORECAST
19.3.2 CANADA: MARKET SIZE & FORECAST
20 EUROPE
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 EUROPE: PRODUCT SEGMENTATION
20.2.2 EUROPE: BIOLOGICS SEGMENTATION
20.2.3 EUROPE: EXPRESSION SYSTEM SEGMENTATION
20.2.4 EUROPE: SCALE OF OPERATION SEGMENTATION
20.2.5 EUROPE: COMPANY SIZE SEGMENTATION
20.3 KEY COUNTRIES
20.3.1 GERMANY: MARKET SIZE & FORECAST
20.3.2 FRANCE: MARKET SIZE & FORECAST
20.3.3 UK: MARKET SIZE & FORECAST
20.3.4 SWITZERLAND: MARKET SIZE & FORECAST
20.3.5 ITALY: MARKET SIZE & FORECAST
20.3.6 SPAIN: MARKET SIZE & FORECAST
21 ASIA PACIFIC
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 APAC: PRODUCT SEGMENTATION
21.2.2 APAC: BIOLOGICS SEGMENTATION
21.2.3 APAC: EXPRESSION SYSTEM SEGMENTATION
21.2.4 APAC: SCALE OF OPERATION SEGMENTATION
21.2.5 APAC: COMPANY SIZE SEGMENTATION
21.3 KEY COUNTRIES
21.3.1 CHINA: MARKET SIZE & FORECAST
21.3.2 JAPAN: MARKET SIZE & FORECAST
21.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
21.3.4 INDIA: MARKET SIZE & FORECAST
21.3.5 AUSTRALIA: MARKET SIZE & FORECAST
22 LATIN AMERICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 LATIN AMERICA: PRODUCT SEGMENTATION
22.2.2 LATIN AMERICA: BIOLOGICS SEGMENTATION
22.2.3 LATIN AMERICA: EXPRESSION SYSTEM SEGMENTATION
22.2.4 LATIN AMERICA: SCALE OF OPERATION SEGMENTATION
22.2.5 LATIN AMERICA: COMPANY SIZE SEGMENTATION
22.3 KEY COUNTRIES
22.3.1 BRAZIL: MARKET SIZE & FORECAST
22.3.2 MEXICO: MARKET SIZE & FORECAST
22.3.3 ARGENTINA: MARKET SIZE & FORECAST
23 MIDDLE EAST AND AFRICA
23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
23.2.1 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
23.2.2 MIDDLE EAST & AFRICA: BIOLOGICS SEGMENTATION
23.2.3 MIDDLE EAST & AFRICA: EXPRESSION SYSTEM SEGMENTATION
23.2.4 MIDDLE EAST & AFRICA: SCALE OF OPERATION SEGMENTATION
23.2.5 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
23.3 KEY COUNTRIES
23.3.1 TURKEY: MARKET SIZE & FORECAST
23.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
23.3.3 UAE: MARKET SIZE & FORECAST
23.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST
24 COMPETITIVE LANDSCAPE
24.1 COMPETITION OVERVIEW
24.2 MARKET SHARE ANALYSIS
25 KEY COMPANY PROFILES
25.1 BOEHRINGER INGELHEIM
25.1.1 BUSINESS OVERVIEW
25.1.2 BOEHRINGER INGELHEIM IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
25.1.3 SERVICE OFFERINGS
25.1.4 KEY STRATEGIES
25.1.5 KEY STRENGTHS
25.1.6 KEY OPPORTUNITIES
25.2 LONZA
25.2.1 BUSINESS OVERVIEW
25.2.2 LONZA IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
25.2.3 SERVICE OFFERINGS
25.2.4 KEY STRATEGIES
25.2.5 KEY STRENGTHS
25.2.6 KEY OPPORTUNITIES
25.3 SAMSUNG BIOLOGICS
25.3.1 BUSINESS OVERVIEW
25.3.2 SAMSUNG BIOLOGICS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
25.3.3 SERVICE OFFERINGS
25.3.4 KEY STRATEGIES
25.3.5 KEY STRENGTHS
25.3.6 KEY OPPORTUNITIES
26 KEY COMPANIES TO WATCH
26.1 ABBVIE
26.1.1 BUSINESS OVERVIEW
26.1.2 ABBVIE IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.1.3 SERVICE OFFERINGS
26.1.4 KEY STRATEGIES
26.1.5 KEY STRENGTHS
26.1.6 KEY OPPORTUNITIES
26.2 CATALENT
26.2.1 BUSINESS OVERVIEW
26.2.2 CATALENT IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.2.3 SERVICE OFFERINGS
26.2.4 KEY STRATEGIES
26.2.5 KEY STRENGTHS
26.2.6 KEY OPPORTUNITIES
26.3 EMERGENT BIOSOLUTIONS
26.3.1 BUSINESS OVERVIEW
26.3.2 EMERGENT BIOSOLUTIONS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.3.3 SERVICE OFFERINGS
26.3.4 KEY STRATEGIES
26.3.5 KEY STRENGTHS
26.3.6 KEY OPPORTUNITIES
26.4 FUJIFILM
26.4.1 BUSINESS OVERVIEW
26.4.2 FUJIFILM BIOSOLUTIONS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.4.3 SERVICE OFFERINGS
26.4.4 KEY STRATEGIES
26.4.5 KEY STRENGTHS
26.4.6 KEY OPPORTUNITIES
26.5 MERCK KGAA
26.5.1 BUSINESS OVERVIEW
26.5.2 MERCK KGAA IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.5.3 SERVICE OFFERINGS
26.5.4 KEY STRATEGY
26.5.5 KEY STRENGTHS
26.5.6 KEY OPPORTUNITIES
26.6 PFIZER
26.6.1 BUSINESS OVERVIEW
26.6.2 PFIZER IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.6.3 SERVICE OFFERINGS
26.6.4 KEY STRATEGIES
26.6.5 KEY STRENGTHS
26.6.6 KEY OPPORTUNITIES
26.7 SERUM INSTITUTE OF INDIA
26.7.1 BUSINESS OVERVIEW
26.7.2 SERUM INSTITUTE OF INDIA IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.7.3 SERVICE OFFERINGS
26.7.4 KEY STRATEGIES
26.7.5 KEY STRENGTHS
26.7.6 KEY OPPORTUNITIES
26.8 WUXI BIOLOGICS
26.8.1 BUSINESS OVERVIEW
26.8.2 WUXI BIOLOGICS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
26.8.3 SERVICE OFFERINGS
26.8.4 KEY STRATEGIES
26.8.5 KEY STRENGTHS
26.8.6 KEY OPPORTUNITIES
27 OTHER PROMINENT VENDORS
27.1 AGC BIOLOGICS
27.1.1 BUSINESS OVERVIEW
27.1.2 SERVICE OFFERINGS
27.2 AJINOMOTO
27.2.1 BUSINESS OVERVIEW
27.2.2 SERVICE OFFERINGS
27.3 ALBANY MOLECULAR RESEARCH (AMRI)
27.3.1 BUSINESS OVERVIEW
27.3.2 SERVICE OFFERINGS
27.4 ASYMCHEM
27.4.1 BUSINESS OVERVIEW
27.4.2 SERVICE OFFERINGS
27.5 BIOCINA
27.5.1 BUSINESS OVERVIEW
27.5.2 SERVICE OFFERINGS
27.6 BIOCON
27.6.1 BUSINESS OVERVIEW
27.6.2 SERVICE OFFERINGS
27.7 COBRA BIOLOGICS
27.7.1 BUSINESS OVERVIEW
27.7.2 SERVICE OFFERINGS
27.8 CHARLES RIVER LABORATORIES
27.8.1 BUSINESS OVERVIEW
27.8.2 SERVICE OFFERINGS
27.9 GOODWIN BIOTECHNOLOGY
27.9.1 BUSINESS OVERVIEW
27.9.2 SERVICE OFFERINGS
27.10 KBI BIOPHARMA
27.10.1 BUSINESS OVERVIEW
27.10.2 SERVICE OFFERINGS
27.11 SANOFI
27.11.1 BUSINESS OVERVIEW
27.11.2 SERVICE OFFERINGS
27.12 BAVARIAN NORDIC
27.12.1 BUSINESS OVERVIEW
27.12.2 SERVICE OFFERINGS
27.13 WACKER BIOTECH B.V
27.13.1 BUSINESS OVERVIEW
27.13.2 SERVICE OFFERINGS
27.14 JUBILANT HOLLISTERSTIER
27.14.1 BUSINESS OVERVIEW
27.14.2 SERVICE OFFERINGS
27.15 NATIONAL RESILIENCE
27.15.1 BUSINESS OVERVIEW
27.15.2 SERVICE OFFERINGS
27.16 NOVASEP
27.16.1 BUSINESS OVERVIEW
27.16.2 SERVICE OFFERINGS
27.17 KEMWELL BIOPHARMA
27.17.1 BUSINESS OVERVIEW
27.17.2 SERVICE OFFERINGS
27.18 MIDAS PHARMA
27.18.1 BUSINESS OVERVIEW
27.18.2 SERVICE OFFERINGS
27.19 ALCAMI
27.19.1 BUSINESS OVERVIEW
27.19.2 SERVICE OFFERINGS
27.20 CAMBREX
27.20.1 BUSINESS OVERVIEW
27.20.2 SERVICE OFFERINGS
27.21 PHARMACEUTICS INTERNATIONAL
27.21.1 BUSINESS OVERVIEW
27.21.2 SERVICE OFFERINGS
27.22 SINGOTA SOLUTIONS
27.22.1 BUSINESS OVERVIEW
27.22.2 SERVICE OFFERINGS
27.23 THERMO FISHER SCIENTIFIC
27.23.1 BUSINESS OVERVIEW
27.23.2 SERVICE OFFERINGS
27.24 BINEX
27.24.1 BUSINESS OVERVIEW
27.24.2 SERVICE OFFERINGS
27.25 CANTON BIOLOGICS
27.25.1 BUSINESS OVERVIEW
27.25.2 SERVICE OFFERINGS
27.26 CHEMPARTNER
27.26.1 BUSINESS OVERVIEW
27.26.2 SERVICE OFFERINGS
27.27 CYTOVANCE BIOLOGICS
27.27.1 BUSINESS OVERVIEW
27.27.2 SERVICE OFFERINGS
28 REPORT SUMMARY
28.1 KEY TAKEAWAYS
28.2 STRATEGIC RECOMMENDATIONS
29 QUANTITATIVE SUMMARY
29.1 MARKET BY PRODUCT
29.1.1 NORTH AMERICA: PRODUCT SEGMENTATION
29.1.2 EUROPE: PRODUCT SEGMENTATION
29.1.3 APAC: PRODUCT SEGMENTATION
29.1.4 LATIN AMERICA: PRODUCT SEGMENTATION
29.1.5 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
29.2 MARKET BY BIOLOGICS
29.2.1 NORTH AMERICA: BIOLOGICS SEGMENTATION
29.2.2 EUROPE: BIOLOGICS SEGMENTATION
29.2.3 APAC: BIOLOGICS SEGMENTATION
29.2.4 LATIN AMERICA: BIOLOGICS SEGMENTATION
29.2.5 MIDDLE EAST & AFRICA: BIOLOGICS SEGMENTATION
29.3 MARKET BY EXPRESSION SYSTEM
29.3.1 NORTH AMERICA: EXPRESSION SYSTEM SEGMENTATION
29.3.2 EUROPE: EXPRESSION SYSTEM SEGMENTATION
29.3.3 APAC: EXPRESSION SYSTEM SEGMENTATION
29.3.4 LATIN AMERICA: EXPRESSION SYSTEM SEGMENTATION
29.3.5 MIDDLE EAST & AFRICA: EXPRESSION SYSTEM SEGMENTATION
29.4 MARKET BY SCALE OF OPERATION
29.4.1 NORTH AMERICA: SCALE OF OPERATION SEGMENTATION
29.4.2 EUROPE: SCALE OF OPERATION SEGMENTATION
29.4.3 APAC: SCALE OF OPERATION SEGMENTATION
29.4.4 LATIN AMERICA: SCALE OF OPERATION SEGMENTATION
29.4.5 MIDDLE EAST & AFRICA: SCALE OF OPERATION SEGMENTATION
29.5 MARKET BY COMPANY SIZE
29.5.1 NORTH AMERICA: COMPANY SIZE SEGMENTATION
29.5.2 EUROPE: COMPANY SIZE SEGMENTATION
29.5.3 APAC: COMPANY SIZE SEGMENTATION
29.5.4 LATIN AMERICA: COMPANY SIZE SEGMENTATION
29.5.5 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
29.6 MARKET BY GEOGRAPHY
29.6.1 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS): GEOGRAPHY SEGMENTATION
29.6.2 FINISHED DOSAGE FORM (FDF): GEOGRAPHY SEGMENTATION
29.6.3 MONOCLONAL ANTIBODIES (MABS): GEOGRAPHY SEGMENTATION
29.6.4 VACCINES: GEOGRAPHY SEGMENTATION
29.6.5 OTHERS: GEOGRAPHY SEGMENTATION
29.6.6 MAMMALIAN: GEOGRAPHY SEGMENTATION
29.6.7 NON-MAMMALIAN: GEOGRAPHY SEGMENTATION
29.6.8 COMMERCIAL: GEOGRAPHY SEGMENTATION
29.6.9 RESEARCH (CLINICAL & PRECLINICAL): GEOGRAPHY SEGMENTATION
29.6.10 LARGE COMPANIES: GEOGRAPHY SEGMENTATION
29.6.11 SMALL & MID-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
30 APPENDIX
30.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the global biopharmaceutical contract manufacturing market size?
What is the expected growth rate of the global biopharmaceutical contract manufacturing market?
Who are the key companies in the biopharmaceutical contract manufacturing market?
Which trends are driving the growth of the global biopharmaceutical contract manufacturing market?
Which region holds the highest global biopharmaceutical contract manufacturing market share?
other RELATED Reports
Medical Device Contract Manufacturing Market - Global Outlook and Forecast 2021-2026
Published : March 2021
Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026
Published : April 2021
Biopharmaceutical Excipients Market - Global Outlook and Forecast 2022-2027
Published : July 2022
Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027
Published : September 2022